EUVIMEDEUVIMED entdecken
Open Access

Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells

Peisen Zheng, Yiqun Xia, Xin Shen, Hui Lu, Yinghua Chen, Chenxin Xu, Chenyu Qiu, Yafei Zhang, Peng Zou, Ri Cui, Xiaoying Huang

International Journal of Biological Sciences · 2024

DOI: 10.7150/ijbs.86160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Peisen Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary Division, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University…. Hauptthemen laut MEDLINE: Thioredoxin Reductase 1, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is one of the most lethal diseases in the world. Although there has been significant progress in the treatment of lung cancer, there is still a lack of effective strategies for advanced cases. Lenvatinib, a multi-targeted tyrosine kinase inhibitor, has achieved much attention due to its antitumor properties. Nevertheless, the use of lenvatinib is restricted by the characteristics of poor efficacy and drug resistance. In this study, we assessed the effectiveness of lenvatinib combined with thioredoxin reductase 1 (TrxR1) inhibitors in human lung cancer cells. Our results indicate that the combination therapy involving TrxR1 inhibitors and lenvatinib exhibited significant synergistic antitumor effects in human lung cancer cells. Moreover, siTrxR1 also showed significant synergy with lenvatinib in lung cancer cells. Mechanically, we demonstrated that ROS accumulation significantly contributes to the synergism between lenvatinib and TrxR1 inhibitor auranofin. Furthermore, the combination of lenvatinib and auranofin can activate endoplasmic reticulum stress and JNK signaling pathways to achieve the goal of killing lung cancer cells. Importantly, combination therapy with lenvatinib and auranofin exerted a synergistic antitumor effect in vivo. To sum up, the combination therapy involving lenvatinib and auranofin may be a potential strategy for treating lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thioredoxin Reductase 1Lung NeoplasmsHumansReactive Oxygen SpeciesAuranofinApoptosisCell Line, TumorCell DeathPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

AuranofinLenvatinibLung cancerROSTrxR1

Substanzen

Thioredoxin Reductase 1Reactive Oxygen SpeciesAuranofinlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Pulmonary Division, Wenzhou Key Laboratory of Interdiscipline and Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Wenzhou Key Laboratory of Heart and Lung, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Zitieren

APA

Zheng, P., Xia, Y., Shen, X., Lu, H., Chen, Y., Xu, C., Qiu, C., Zhang, Y., Zou, P., Cui, R., & Huang, X. (2024). Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.86160

Vancouver

Zheng P, Xia Y, Shen X, Lu H, Chen Y, Xu C, et al. Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells. International Journal of Biological Sciences. 2024. doi:10.7150/ijbs.86160

BibTeX
@article{Zheng2024,
  author = {Zheng, Peisen and Xia, Yiqun and Shen, Xin and Lu, Hui and Chen, Yinghua and Xu, Chenxin and Qiu, Chenyu and Zhang, Yafei and Zou, Peng and Cui, Ri and Huang, Xiaoying},
  title = {Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells},
  journal = {International Journal of Biological Sciences},
  year = {2024},
  doi = {10.7150/ijbs.86160}
}
Kostenlos starten →